NYSEARCA:PPH

Vaneck Pharmaceutical Etf ETF News

etoro logo Buy PPH
*Your capital is at risk
$101.22
-1.06 (-1.04%)
At Close: Jun 02, 2026
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.
VanEck Pharmaceutical ETF offers a concentrated portfolio focused exclusively on drug manufacturers. iShares Global Healthcare ETF provides broader diversification across more than 100 companies in th
The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on Decemb
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline.
Avalon Trust Co lessened its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 1.8% during the undefined quarter, according to the company in its most recent disclosure with the SEC. Th
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on Decemb
Adamsbrown Wealth Consultants LLC lowered its position in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 30.1% in the third quarter, according to its most recent 13F filing with the Securities a
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund's concentrated bet on GLP-1 manufacturers makes this
BBH: Mature Biotech Exposure, But Limited Growth Ahead
The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to cho

Why PPH Keeps Working When Single Themes Break

03:35pm, Wednesday, 17'th Dec 2025
The VanEck Pharmaceutical ETF offers concentrated exposure to large-cap global pharma leaders, balancing growth, defensive, and non-drug cash flow stabilizers. PPH has demonstrated resilience, outperf
Fisher Asset Management LLC reduced its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 98.8% in the second quarter, according to the company in its most recent 13F filing with the Se
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE